OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
08/13/2026
Back to search
Official data from USPTO
SAMYANG
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
08/13/2026
Trademark type
Combined
Nice classes
5
Filing date
12/18/2024
Registration date
04/14/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/14/2026
Last transaction
08/13/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
03
Owner location
KR
Examiner
MANCA, ALBERTO I
Law office
L80
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Samyang Holdings Corporation
Representatives
Richard Y. Kim Snell & Wilmer L.L.P.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for health carenutritional supplements; vaccines; food supplements; natural remedy preparations for the treatment of hangover with vitamin B1 containing yeast-based ingredients for medical purposes; natural remedy preparations for the treatment of hangover with vitamin B2 containing yeast-based ingredients for medical purposes; natural remedy preparations for the treatment of hangover with vitamin C containing yeast-based ingredients for medical purposes; vitamin and mineral dietary supplements; veterinary substances and preparationsveterinary vaccines; medicinal preparations for the mouth to be applied in the form of dropscapsulestablets and compressed tablets; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; filled syringes for medical purposes containing pharmaceuticals in the nature of anti-infectives; antibiotic ointments for pharmaceutical purposes; cachets for pharmaceutical purposes in the nature of pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations being hormone preparations in the nature of preparations for the suppression of hormones for human use; pills for pharmaceutical purposes for the treatment of cancer and prevention of viruses; pills for pharmaceutical purposespills for the treatment of viralbacterialfungal infection and immune disorder; ferments for pharmaceutical purposes; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films and coatings for tablets that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of dissolvable films that facilitate the delivery of nutritional supplements; drugs for medical purposespharmaceutical preparations for the treatment of respiratory diseases; pre-filled syringes for medical purposes sold filled with pharmaceuticals for skin careskin regenerationskin moisturizationaesthetic treatmentshyaluronic acidsBotulinum toxinpharmaceutical preparations for the treatment of neurological disordersmuscle dystoniassmooth muscle disordersautonomic nerve disordersheadacheswrinkleshyperhydrosissports injuriescerebral palsyspasmstremors and pain; pharmaceutical preparations for skin careskin anti-aging preparations for medical use; pharmaceuticals preparationpharmaceutical fillers in the nature of injectable dermal fillersbone fillers consisting of living materialsbone void fillers consisting of natural materials for medical use; pharmaceutical syringes prefilled with medical hyaluronic acid as the main ingredient; medicinal drinks; pharmaceutical drugsantipyreticsanti-infectivesantineoplasticsdiureticspharmaceutical preparations for the treatment of immune system disordersdisorders of the central nervous systemendocrine disordersgastrointestinal diseasesdermatological diseasesinfectious diseasescardiovascular diseasesrespiratory diseases; medicinal infusions for treating dermatologicalkidneyhearturologicalcirculatory diseasesas well as cancer and inflammatory conditions; pharmaceuticalsantivirals; pharmaceuticalspharmaceuticals for the treatment of cancer; human vaccine preparations; medicines for human purposes for dental purposes; medicines for human purposes for the treatment of cardiovascular and cerebrovascular diseases; medicines for human purposes for the treatment of cancer; medicines for human purposes for the treatment and prevention of iron deficiency and anemia; delivery agents in the form of coatings for tablets that facilitate the delivery of nutritional supplements; pharmaceutical preparations for skin carepharmaceutical preparations for wrinkle treatment; injectable pharmaceutical preparations in the nature of injectable dermal fillers for filling wrinkle in the form of gel; injectable dermal fillers; implantable medicines for the prevention and treatment of diabetes; implantable medicines for the prevention and treatment of cardiovascular diseases; implantable medicines for the prevention and treatment of central nervous system diseases; implantable medicines for the prevention and treatment of cancer; implantable medicines for the prevention and treatment of metabolism diseases; nutraceutical preparations for therapeutic and medical purposesnutraceuticals for the treatment of cancerdiabetesheadaches; dermatological pharmaceutical products; gelscreams and solutions for dermatological use; pharmaceutical preparations for use in dermatologyinjectable dermal fillers; pharmaceutical preparations for skin carepharmaceutical preparations for skin whitening; pharmaceutical preparations for skin carepharmaceutical preparations for skin moisturizing; pharmaceutical preparations for skin careinjectable pharmaceutical preparations for skin moisturizing; pharmaceutical preparations for skin care; pharmaceutical preparations for skin carepharmaceutical preparations for skin regeneration; antibiotics; nicotine patches for use as aids to stop smoking; pharmaceutical preparations used in the smoking cessationsmoking cessation preparations; anti-adhesion agents for medical purposesanti-adhesion gels for use with wound drainage devices; surgical glues; denture adhesives; dental adhesives; medical adhesives for binding internal tissue; medical adhesives for binding wounds; hemostatics for medical purposes; transdermal patches for medical treatment for use in the treatment of psoriasisacnefungal infectionskin disorders; anti-cancer preparations
Publications
History of USPTO decisions and trademark events.
27 publications found
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/27/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
07/26/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/14/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/14/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
04/14/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/24/2026
PUBO
PUBLISHED FOR OPPOSITION
02/24/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/18/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/29/2026
XAEC
EXAMINER'S AMENDMENT ENTERED
01/29/2026
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/29/2026
GNEA
EXAMINERS AMENDMENT E-MAILED
01/29/2026
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/29/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/23/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/23/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/23/2026
RFNT
REFUSAL PROCESSED BY IB
08/23/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/02/2025
RFRR
REFUSAL PROCESSED BY MPU
08/02/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/12/2025
CNRT
NON-FINAL ACTION WRITTEN
06/11/2025
DOCK
ASSIGNED TO EXAMINER
06/04/2025
MAFR
APPLICATION FILING RECEIPT MAILED
03/21/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/21/2025
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
03/21/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/27/2025
Continuous trademark protection
Get notified about every new filing that threatens SAMYANG or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.